Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.44 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973333 | 1.00 | MAPK1 (0.47) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL10893872 | 0.94 | MAPK1 (0.50) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL15081856 | 0.92 | MAPK1 (0.54) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL15064152 | 0.92 | MAPK1 (0.54) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL15081854 | 0.92 | MAPK1 (0.54) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL12575336 | 0.85 | CETP (0.53) | MAPK1HTTPOLBMAPTNTRK1 | |
| SCHEMBL11020420 | 0.85 | CETP (0.53) | MAPK1HTTPOLBMAPTNTRK1 | |
| SCHEMBL541119 | 0.85 | CETP (0.53) | MAPK1HTTPOLBMAPTNTRK1 | |
| SCHEMBL10764966 | 0.85 | MAPT (0.65) | MAPK1HTTPOLBMAPTAPEX1 | |
| SCHEMBL10818398 | 0.84 | POLB (0.54) | MAPK1HTTPOLBMAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | claimed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | claimed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | claimed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | claimed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | claimed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | MAPK1 3566/4885HTT 2283/4885POLB 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.